％0期刊文章％A Borisov，Sergey％Danila，Edvardas％A Maryandyshev，Andrei％A Dalcolmo，Margareth％A Miliauskas，Skaidrius％A Kuksa，Liga％A Manga，Manga，Selene％A Skrahina，Alena，Alena，Alena，Alena a Diktanas，Saulius％saulius％A Codecasa, Luigi Ruffo %A Aleksa, Alena %A Bruchfeld, Judith %A Koleva, Antoniya %A Piubello, Alberto %A Udwadia, Zarir Farokh %A Akkerman, Onno W. %A Belilovski, Evgeny %A Bernal, Enrique %ABoeree，Martin J.％ACadiñanosLoidi，Julen％A CAI，Qingshan％A CEBRIAN GALLARDO，JOSE JOAPAIN％a dara，Masoud％Davidavičienė，Edita％forsman a Forsman，Lina Davies％de Los a de Los a de los a de los a jorge a denholm a denholm，a denholm，a denholm，a denholm，a denholm，a denholm，贾斯汀％adrakšienė，jacinta％duarte，raquel％a elamin，seifeldin eltaeb％a escobar salinas，nadia％a ferrarese，毛里齐奥％a filippov，alexey％a garcia，ana％agarcía-garcía-garcía-garcía，josémaríapagarcía，, Ieva %A Gavazova, Blagovesta %A Gayoso, Regina %A Gomez Rosso, Roscio %A Gruslys, Vygantas %A Gualano, Gina %A Hoefsloot, Wouter %A Jonsson, Jerker %A Khimova, Elena %A Kunst, Heinke %A拉法（Rafa）Laniai-Laborínel％a li，yang％a magis-escurra，cecile％a manfrin，vinicio％marchese，valentina％amartínezRobles，elena％atteelli，alberto a mazza a mazza-stalder，jesica％a moschos，charalampos a muschos％amuñoz--muñoz--muñoz---Torrico, Marcela %A Mustafa Hamdan, Hamdan %A Nakčerienė, Birutė %A Nicod, Laurent %A Nieto Marcos, Magnolia %A Palmero, Domingo Juan %A Palmieri, Fabrizio %A Papavasileiou, Apostolos %A Payen, Marie-Christine %APontarelli，Agostina％AQuirós，Sarai％A Rendon，Adrian％A Saderi，Laura％Ašmite，Agnese％A Solovic，Ivan％A Souleymane，Mahamadou Bassirou％A Tadolini，Tadolini，Marina％A van den den den boom，van den den boom，van den den boom a martin％a martin％a martin％a martin％a martin％，Martin％，Martin％，Martin％，Martin％marisa％a viggiani，pietro％a yedilbayev，askar％a zablockis，rolandas％a zhurkin，dmitry％a Zignol，Matteo％a visca，Dina％spanevello，antonio a caminero a caminero，a caminero，JoséA。％a tiberi，Simon％A Centis，Rosella％A D'Ambrosio，lia％A Pontali，Emanuele％A Sotgiu，Giovanni％A Migliori，Giovanni Battista％T，在治疗药物抗药性的结核病的治疗中不良事件的育活情况：第一全球报告％d 2019％r 10.1183/13993003.01522-2019％J欧洲呼吸杂志％p 1901522％v 54％n 6％x世界卫生组织（WHO）建议国家实施药物消毒和收集有关活动药物安全监测的信息（ADSM）和不良事件的管理。这项前瞻性研究的目的是评估一组新的TB患者的抗结核药物（TB）药物的不良事件的频率和严重程度（TB）药物（即。 bedaquiline, delamanid) and repurposed (i.e. clofazimine, linezolid) drugs, based on the WHO aDSM project. Adverse events were collected prospectively after attribution to a specific drug together with demographic, bacteriological, radiological and clinical information at diagnosis and during therapy. This interim analysis included patients who completed or were still on treatment at time of data collection.Globally, 45 centres from 26 countries/regions reported 658 patients (68.7% male, 4.4% HIV co-infected) treated as follows: 87.7% with bedaquiline, 18.4% with delamanid (6.1% with both), 81.5% with linezolid and 32.4% with clofazimine. Overall, 504 adverse event episodes were reported: 447 (88.7%) were classified as minor (grade 1–2) and 57 (11.3%) as serious (grade 3–5). The majority of the 57 serious adverse events reported by 55 patients (51 out of 57, 89.5%) ultimately resolved. Among patients reporting serious adverse events, some drugs held responsible were discontinued: bedaquiline in 0.35% (two out of 577), delamanid in 0.8% (one out of 121), linezolid in 1.9% (10 out of 536) and clofazimine in 1.4% (three out of 213) of patients. Serious adverse events were reported in 6.9% (nine out of 131) of patients treated with amikacin, 0.4% (one out of 221) with ethionamide/prothionamide, 2.8% (15 out of 536) with linezolid and 1.8% (eight out of 498) with cycloserine/terizidone.The aDSM study provided valuable information, but implementation needs scaling-up to support patient-centred care.Previous evidence on adverse events is available from single studies. This global project (658 patients from 26 countries) demonstrates aDSM is feasible and serious adverse events of recommended drugs are reasonably low (overall 57 out of 504, 11.3%). http://bit.ly/2kzvbqe %U //www.qdcxjkg.com/content/erj/54/6/1901522.full.pdf